Lung cancer is the leading cause of cancer death in the United States. Cure rates from primary treatment are low (approximately 15%). There is an urgent need to develop compounds, which can prevent the disease in individuals with a history of cigarette smoking and other factors associated with increased lung cancer risk. A number of compounds have been tested but trials to date have not resulted in a decrease of lung cancer incidence. In fact, two large-scale chemoprevention trials that evaluated beta-carotene in active and former smokers, resulted in an increase of incidence and mortality from lung cancer. Recently, the focus of lung cancer chemoprevention has shifted towards investigations using inhibitors of inflammatory response pathways and inhibitors of growth factor signaling pathways. A novel class of agents has been developed that induce apoptosis. Exisulind (Aptosyn) is the first agent in this class, and it has shown promise in chemoprevention of colorectal carcinoma by reducing the number of size of adenomatous polyps in humans. In animal studies, this agent has resulted in a reduction of carcinogen-induced lung cancer. To test the clinical utility of this agent in lung cancer prevention, we propose to perform a double-blind, placebo-controlled, randomized, clinical efficacy trial in former smokers. Participants will be stratified by lung cancer risk based on airway obstruction, prior history of completely resected stage I non-small cell lung cancer, and the histopathology of bronchial biopsies. They will be randomized 2:1 to drug vs. placebo. A surrogate marker of lung cancer, the proliferation marker Ki-67, will be used as the primary endpoint. Other markers previously and currently investigated by us and others (MCM2, hnRNP, apoptosis, cytokine response profiles, (epi) genetic alterations, morphology) will be explored as surrogate trial endpoints. Exisulind will be given orally at a dose of 500 mg daily for 6 months. With 93 evaluable participants randomized to exisulind, the study will have 80% power to detect a 50% or greater decrease in the mean Ki-67 labelling index as a result of treatment. Since we anticipate a 25% attrition rate, we are planning to enroll a total of 186 subjects over 4 years. Given the number of eligible subjects at our institution that already participate in early detection trials, we are confident that the goal of this proposed study can be achieved during the 5-years of funding. The data generated by these investigations will be important for future decisions on large-scale chemoprevention trials using disease incidence and mortality as endpoints.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA101222-01
Application #
6641928
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Szabo, Eva
Project Start
2003-09-15
Project End
2008-08-31
Budget Start
2003-09-15
Budget End
2004-08-31
Support Year
1
Fiscal Year
2003
Total Cost
$976,569
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Gray, Jhanelle E; Altiok, Soner; Alexandrow, Mark G et al. (2013) Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer 119:1023-32
Lee, Sang-Haak; Chen, Tingan; Zhou, Jun et al. (2010) Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer 11:169-75
Koomen, John M; Haura, Eric B; Bepler, Gerold et al. (2008) Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7:1780-94
Munoz-Antonia, Teresita; Muro-Cacho, Carlos; Sharma, Swati et al. (2007) Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer 110:1527-31
Zheng, Z; Cantor, A; Bepler, G (2006) A global genome damage score predictive of lung cancer patients outcome. Oncogene 25:4491-4
Haura, Eric B; Zheng, Zhong; Song, Lanxi et al. (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11:8288-94
Zheng, Zhong; Bepler, Gerold; Cantor, Alan et al. (2005) Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest 128:308-16
Ferraro, Bernadette; Bepler, Gerold; Sharma, Swati et al. (2005) EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23:1921-6
Haura, Eric B; Cress, W Douglas; Chellappan, Srikumar et al. (2004) Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer 6:113-22